Last reviewed · How we verify
Dabigatran; Rivaroxaban
Both dabigatran and rivaroxaban are direct oral anticoagulants that inhibit key clotting factors to prevent blood clot formation.
Both dabigatran and rivaroxaban are direct oral anticoagulants that inhibit key clotting factors to prevent blood clot formation. Used for Atrial fibrillation for stroke prevention, Deep vein thrombosis (DVT) treatment and prevention, Pulmonary embolism (PE) treatment and prevention.
At a glance
| Generic name | Dabigatran; Rivaroxaban |
|---|---|
| Also known as | Pradaxa, Xarelto |
| Sponsor | University Hospital, Grenoble |
| Drug class | Direct oral anticoagulant (DOAC) |
| Target | Dabigatran: Factor IIa (thrombin); Rivaroxaban: Factor Xa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Dabigatran is a direct thrombin inhibitor that blocks Factor IIa, preventing the conversion of fibrinogen to fibrin and clot formation. Rivaroxaban is a Factor Xa inhibitor that blocks the intrinsic and extrinsic coagulation pathways. Both drugs provide rapid anticoagulation without requiring monitoring, unlike warfarin.
Approved indications
- Atrial fibrillation for stroke prevention
- Deep vein thrombosis (DVT) treatment and prevention
- Pulmonary embolism (PE) treatment and prevention
- Acute coronary syndrome (rivaroxaban)
Common side effects
- Bleeding (major and minor)
- Dyspepsia
- Gastrointestinal bleeding
- Anemia
Key clinical trials
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants) (NA)
- PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
- Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia (PHASE4)
- Anticoagulation in Patients With Venous Thromboembolism and Cancer
- High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France
- SNAP AF-52: Dose Appropriateness and Adherence to Oral Anticoagulation in Adults ≥65 With Atrial Fibrillation in Primary Care (Ordu, Türkiye)
- Monitoring of NOAC Therapy: Standardizing Reference Intervals
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dabigatran; Rivaroxaban CI brief — competitive landscape report
- Dabigatran; Rivaroxaban updates RSS · CI watch RSS
- University Hospital, Grenoble portfolio CI